The death wasn’t due to Beam Therapeutics’ sickle cell disease therapy, BEAM-101, but was instead attributed to the preconditioning treatment needed before the genetic medicine is infused. A different Beam program in preclinical development could avoid the need for toxic preconditioning; data from both programs will be presented during the upcoming American Society of Hematology annual meeting.
The post Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results appeared first on MedCity News.
